Correspondence

Characterisation of human articular cartilage link proteins from normal and osteoarthritic cartilage: a comment

Sir, Ryu et al. studied the ability of human articular cartilage link proteins to stabilise the interaction between proteoglycan subunit (from bovine tracheal cartilage) and high molecular weight hyaluronate. They used Sepharose 2B gel chromatography to demonstrate the interaction, equating material eluting in the void volume of the column with aggregated material.

Their Fig. 2 reproduced below shows the gel elution profile they obtained.

When interpreting their results it is important to note the apparently low recovery of material applied to the column. The Sepharose 2B column used was small (1 × 22 cm) and run at a high flow rate (18 ml/hour). The void volume (V0) of such a column would occur in the region of 8 ml, and effectively all the material would be eluted by one column volume of eluant. Considering the major peak in the upper half of Fig. 2, fractions 10–20 should contain the eluted uronate in under about 20 ml of eluant. The area under this curve determined gravimetrically corresponds to approximately 2.8 µg of uronate, assuming that uronate is measured in µg/ml, whereas around 120 µg of uronate would be present in the 500 µg of proteoglycan applied to the column. At pH 4 only around 2 µg of uronate appears to have been eluted. The same conclusions apply to the elution profiles in the lower half of the diagram.

I would also question the validity of equating material eluting in the void volume of a Sepharose 2B column with aggregated material. I would be surprised if rechromatography of the leading half of the void volume peak did not lead to the redistribution of some material into the included volume. As far as I am aware, Sepharose 2B chromatography has not allowed the isolation and study of 100% aggregated material. This consideration clearly also bears on the interpretation of a number of other similar studies.

Department of Medicine, D. W. BULLIMORE
St James's Hospital, Leeds LS9 7TF

Reference


Sir, Dr Bullimore is correct with his calculations on the quantity of uronic acid which we should have obtained eluting off the Sepharose 2B column. The ordinate of this graph is in error. It should read uronic acid (µg × 10^-2). The fraction volumes were not 1 ml but 0.6 ml and the void volume of the column is approximately 7.5 ml.

I agree with Dr Bullimore's comment that 2B column chromatography does not allow one to conclude that all the uronic acid containing material eluting in the void volume is aggregate. The purpose of this article was simply to demonstrate that osteoarthritic link was effective in shifting the bulk of the proteoglycans into the void volume, presumably through stabilisation of the subunits with hyaluronic acid.

Fig. 2 CL-Sepharose 2B filtration of proteoglycan aggregates.
Chromosomes in rheumatoid arthritis

Sir, Lymphoproliferative disorders are more frequently found in patients with autoimmune disease than in normal persons. Isomaki et al. showed an increased risk of leukaemia, lymphoma, Hodgkin's disease, and multiple myeloma in rheumatoid arthritis (RA) patients. These investigators postulated that a continuous immunological stimulation in RA could cause proliferation and malignant transformation of the immunologically competent cell clones. Green et al. believe that immunodeficiency in patients with autoimmune disease may be a factor in the development of lymphoproliferative disease.

We found marked chromosomal abnormalities in a patient with lymphoma who was treated with intra-articular radioactive gold (198Au) for severe RA. Although we were tempted to conclude the chromosomal abnormalities found in our patient were due to her 198Au treatment, we were unable to exclude the possibility that the phenylbutazone and prednisone or the development of her lymphoma or RA may have been the cause of the chromosomal abnormalities. This communication reports our chromosomal findings of 21 RA patients with various treatments and of 28 controls.

Heparinised peripheral blood was obtained for cytogenetic studies from 21 active RA patients. Five patients received 10 mCi of intra-articular 198Au; 14 received intramuscular nonradioactive gold; and 2 received full therapeutic doses of aspirin (7800 mg/day). The controls consisted of 28 hospital employees without any known illnesses. Peripheral blood was cultured in TC 199 tissue culture medium, enriched with either autologous plasma or fetal calf serum and stimulated with phytohemagglutinin (PHA) according to the method used in our laboratory. After incubation at 37°C for three days the cultures were exposed to colcemid at a concentration of 0.16 μg/ml for one hour. The cells were then exposed to 0.075 M KCl for half an hour, fixed with acetoalcohol, and the slides made by the air-dried method. The slides were stained with Giemsa and analysed for chromosomal breakages as described.

The mean rate of chromosomal breakages was 8.6 ± 2.4 (SEM) in the 5 RA patients treated with 198Au; 9.4 ± 1.43 in the 14 treated with nonradioactive gold; and 5.5 ± 1.4 in the 2 treated with high doses of aspirin. The 28 controls had a frequency of 3.67 ± 0.56. The mean difference of the chromosomal breakages among the RA patients, treated with radioactive or nonradioactive gold, was not statistically significant. But the difference between the RA patients and the controls was significant.

Acquired chromosomal abnormalities can be seen in patients exposed to radiation, virus, and certain chemicals or in patients with various malignant diseases. The marked chromosomal abnormalities found and reported in our patients with lymphoma, treated with 198Au for her RA, must not have been caused by the radioactivity of the 198Au per se. This conclusion is based on our present finding that significant chromosomal breakages are also seen in RA patients treated with nonradioactive gold. Although it is possible that the chromosomal abnormalities found in our RA patients were associated with their primary disease rather than their treatment, we cannot make this conclusion based on our present data, since all our patients were treated with various methods. Also, it is not possible to study RA patients not treated with aspirin to rule out this possibility.

Monroe Community Hospital & Strong Memorial Hospital, Rochester, NY 14624, USA

References